يعرض 1 - 15 نتائج من 15 نتيجة بحث عن '"S. Tsurkan A."', وقت الاستعلام: 0.52s تنقيح النتائج
  1. 1
    Academic Journal

    المصدر: Siberian journal of oncology; Том 18, № 6 (2019); 75-81 ; Сибирский онкологический журнал; Том 18, № 6 (2019); 75-81 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2019-18-6

    وصف الملف: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/1246/688; Yan S., L. Yang., Lu L., Guo Q., Hu X., Yuan Y., Li Y., Wu M., Zang J. Improved pharmacokinetic characteristics and bioactive effects of anticancer enzyme delivery systems. Expert opinion on drug metabolism and toxicology. 2018; 14: 951–960. doi:10.1080/17425255.2018.1505863.; Mazzaferro S., Bouchemal K., Ponchel G. Oral delivery of anticancer drugs I: general considerations. Drug Discov Today. 2013 Jan; 18(1–2): 25–34. doi:10.1016/j.drudis.2012.08.004.; Sparreboom A., De Jonge M. J. A., Verweij J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer. 2002; 38: 1822. doi:10.1016/S0959-8049(01)00322-7.; Андронова Н.В., Черкасова Ж.Р., Цуркан С.А., Смирнова Г.Б., Трещалина Е.М. Оценка интернализации АФП-содержащего нековалентного комплекса Аимпила в модели изолированного отрезка тонкой кишки крыс. Российский онкологический журнал. 2016; 21(6): 308–311. doi:10.18821/1028-9984-2016-21-6-308-311.; Tcherkassova J., Abramovich C., Moro R., Chen C., Schmit R., Gerber A., Moro R. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumour Biol. 2011 Aug; 32(4): 831–8. doi:10.1007/s13277-011-0186-1.; Réti-Nagy K., Malanga M., Fenyves E., Szente L., Vámosi G., Váradi J., Bácskay I., Fehér P., Ujhelyi Z., Róka E., Vecsernyés M., Balogh G., Vasvári G., Fenyvesi F. Endocytosis of fluorescent cyclodextrins by intestinal Caco-2 cells and its role in paclitaxel drug delivery. Int J Pharm. 2015 Dec 30; 496(2): 509–17. doi:10.1016/j.ijpharm.2015.10.049.; Tsurkan S., Tcherkassova J., Gorbunova V., Treshalina H. New drug AIMPILA targeted to AFP receptor: Oral anticancer therapy and biodistribution in vivo. J Clin Oncol. 2018: 36 (15_suppl): e24232–24232. doi:10.1200/JCO.2018.36.15.; Pokrovsky V.S., Treshalina H.M., Lukasheva E.V., Sedakova L.A., Medentzev A.G., Arinbasarova A.Yu., Berezov T.T. Enzymatic properties and anticancer activity of L-lysine alpha-oxidase from Trichoderma cf. aureoviride Rifai ВКМF-4268D. Anticancer Drugs. 2013 Sep; 8(24): 846–851. doi:10.1097/CAD.0b013e328362fbe2.; Покровский В.С., Трещалина Е.М., Лукашева Е.В., Седакова Л.А. Разработка режима внутривенного введения лизин-альфа-оксидазы из Trichoderma cf. aureoviride Rifai вкmf-4268 под контролем переносимости и эффективности лечения. Российский онкологический журнал. 2013; 2: 10–14.; Kusakabe H., Kodama K., Kuninaka F., Yoshino Y., Misono H., Soda K. A new antitumor enzyme, L-lysine alpha-oxidase from Trichoderma viride. Purification and enzymological properties. J Biol Chem. 1980. 255: 976–981.; Lukasheva E.V., Ribakova Y.S., Fedorova T.N., Makletsova M.G., Arinbasarova A.Y., Medentzev A.G., Berezov T.T. Isolation and properties of L-Lysine α-oxidase from Trichoderma cf. aureoviride Rifai ВКМ F-4268D. Microbiologia. 2012; 81: 594–594. doi:10.1134/S0026261712050037.; Asano Y., Yasukawa K. Identification and development of amino acid oxidases. Curr Opin Chem Biol. 2019 Apr; 49: 76–83. doi:10.1016/j.cbpa.2018.10.020.; Щекотихин А.Е., Трещалина Е.М., Трещалин И.Д. Пероральные противоопухолевые агенты и метод лечения рака. Патент РФ № 2639479. 2017.; Treshalina H.M., Romanenko V.I., Kaluzhny D.N., Treshalin M.I., Nikitin A.A., Tikhomirov A.S., Shchekotikhin A.E. Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation. Eur J Pharm Sci. 2017 Nov 15; 109: 631–637. doi:10.1016/j.ejps.2017.09.025.; Tikhomirov A.S., Lin C.Y., Volodina Y.L., Dezhenkova L.G., Tatarskiy V.V., Schols D., Shtil A.A., Punit Kaur, Pin Ju Chueh, Shchekotikhin A.E. New antitumor anthra [2, 3-b] furan-3-carboxamides: Synthesis and structure-activity relationship. Eur J Med Chem. 2018 Mar 25; 148: 128–139. doi:10.1016/j.ejmech.2018.02.027.; Заведос. Лекарственный справочник ГЭОТАР [Интернет]. URL: https://www.lsgeotar.ru/zavedos-3422.html. (дата обращения: 16.04.2019).; Amin M., Pourshohodb A., Kheirollahb A., Afrakhtehb M., Gholami-Borujenic F., Zeinalid M., Jamalanef M. Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumabconjugated liposomes. J Drug Delivery Sci Technol. 2018; 47: 209–214. doi:10.1016/j.jddst.2018.07.017.; https://www.siboncoj.ru/jour/article/view/1246

  2. 2
    Academic Journal

    المصدر: Siberian journal of oncology; Том 18, № 5 (2019); 18-28 ; Сибирский онкологический журнал; Том 18, № 5 (2019); 18-28 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2019-18-5

    وصف الملف: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/1184/663; Jackson S.E., Chester J.D. Personalised cancer medicine. Int J Cancer. 2015 Jul 15; 137(2): 262–6. doi:10.1002/ijc.28940.; Mascaux C., Tomasini P., Greiller I., Barilsi F. Personalised medicine for nonsmall cell lung cancer. Eur Respir Rev. 2017 Nov 15; 26(146). pii: 170066. doi:10.1183/16000617.0066-2017.; Baxendale S., van Eedan F., Wilkinson R. The power of Zebrafish in Personalised Medicine. Adv Exp Med Biol. 2017; 1007: 179–197. doi:10.1007/978-3-319-60733-7_10.; Ballman K.V. Biomarker: Predictive or Prognostic? J Clin Oncol. 2015 Nov 20; 33(33): 3968–71. doi:10.1200/JCO.2015.63.3651.; Huang J., Hu W., Sood A.K. Prognostic Biomarkers in Ovarian Cancer. Cancer Biomark. 2010–2011; 8(0): 231–251. doi:10.3233/CBM2011-0212.; Weigel M.T., Dowsett M. Current and emerging biomarkers in breast cancer: prognostic and predictive. Endocr Relat Cancer. 2010 Sep 23; 17(4): R245–62. doi:10.1677/ERC-10-0136.; Das V., Kalita J., Pal M. Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacother. 2017 Mar; 87: 8–19. doi:10.1016/j.biopha.2016.12.064.; Rodriguez-Vida A., Strijbos M., Hutson T. Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open. 2016 May 25; 1(3): e000013. doi:10.1136/esmoopen-2015-000013.; Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C.; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct; 24 Suppl 6: vi24–32. doi:10.1093/annonc/mdt333.; Parker C., Gillessen S., Heidenreich A., Horwich A.; ESMO Guidelines Committee. ESMO clinical guidelines for diagnosis, treatment and follow-up for prostate cancer. Ann Oncol. 2015 Sep; 26 Suppl 5: v69–77. doi:10.1093/annonc/mdv222.; Minimum clinical recommendations ESMO [Internet]. URL: https://www.jastro.or.jp/customer/guideline/2016/10/esmo_index.pdf (cited 10.01.2019).; Семёнова А.И. Мониторинг эффективности лечения и выявление рецидивов с помощью биомаркеров. Практическая онкология. 2011; 12(4): 171–177.; Moro R., Tcherkassova J., Song E., Shen G., Moro R., Schmid R., Hu X., Kummer A., Chen C. A new broad-spectrum cancer marker. In-Vitro Diagnostic Technology. 2005; 1–6.; Moro R., Gulyaeva-Tcherkassova J., Stieber P. Icreased AFPReceptor (RECAF) values in the serum of patients with early stages of breast cancer. J Curr Oncol. 2012; 19(1): e1–8. doi:10.3747/co.19.979.; Tcherkassova J., Abramovich C., Moro R., Chen C., Smit R., Gerber A., Moro R. Combination of CA125 and RECAF biomarkers for early detection of Ovarian cancer. Tumor Biol. 2011; 32(4): 831–838. doi:10.1007/s13277-011-0186-1.; Moro R., Uriel J. Early localization of AFP in the developing nervous system of the chicken. Oncodevelop Biol Med. 1981; 2: 391–398.; Villacampa M.J., Moro R., Naval J., Failly-Crepin C. Lampreave F., Uriel J. RECAFs in a human breast cancer cell line. Biochem Biophys Res Commun. 1984; 122: 1322–1327. doi:10.1016/0006-291X(84)91236-1.; Jacobson H.I., Bennett J.A., Mizejewski G.J. Inhibition of estrogendependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol. Cancer Res. 1990; 50(2): 415–420.; Mizejewski G.J., Phillips L., Stoll W. In vitro studies of the abortogenic potential of anti-serum to alpha-fetoprotein. Int J Immunopharmacol. 1981; 3(1): 87–95.; Moro R., Tamaoki T., Wegmann T.G., Longenecker B.M., Laderoute M.P. Monoclonal antibodies directed against a widespread oncofetal antigen: the alpha-feloprotein receptor. Tumour Biol. 1993; 14(2): 116–30. doi:10.1159/000217864.; Laderoute M. A new perspective on the nature of the cancer problem: anticellular senescence. Mol Carcinog. 1994 Jul; 10(3): 125–33.; Uriel J., Villacampa M.J., Moro R., Naval l., Failly-Crepin C. Uptake of radiolabeled alpha•fetoprolein by mouse mammary carcinomas and its usefulness in tumor scintigraphy. Cancer Res. 1984; 44: 5314–5319.; Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., Winget M., Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001 Jul 18; 93(14): 1054–61. doi:10.1093/jnci/93.14.1054.; Uriel J., Poupon M.F., Geuskens M. Alphafoecoprolein uptake by cloned cell lines derived from a nickel•induced rat rhabdomyosarcoma. J Cancer. 1983; 48: 261–269.; Suzuki Y., Zeng C.Q., Alpert E. Isolation and partial characterization of a specific alpha-fetoprotein receptor on human monocytes. Clin Invest. 1992; 90: 1530–6. doi:10.1172/JCI116021.; Torres J.M., Darracq N., Uriel J. Membrane proteins from Lymphoblastoid cells showing cross-affinity for alpha-fetoprotein and albumin. Isolation and characterization. Biochim Biophys Acta. 1992 Sep 4; 1159(1): 60–6.; Kanevsky V.Yu., Pozdnyakova L.P., Aksenova O.A., Severin S.E., Katukov V.Yu., Severin E.S. Isolation and characterization of AFP binding proteins from tumor and fetal human tissues. Biochem Mol Biol Int. 1997; 41(6): 1143–51.; Черешнев В.А., Родионов С.Ю., Васильев Н.В., Орлов О.А., Черкасов В.А. Иммунотерапия злокачественных опухолей альфафетопротеином человека как этап комбинированного и комплексного лечения онкологических больных [Интернет]. URL: http://www.a-fp.ru/articles/immunoterapiya-zlokachestvennyh-opuholey-alfa-fetoproteinomcheloveka-kak-etap (дата обращения: 10.01.2019).; Tcherkassova J., Tsurkan S., Smirnova G., Borisova J., Moro R., Treshalina H. Binding characterization of the targetingdrug AIMPILA to AFP receptors in human tumor xenografts. Tumour Biol. 2017 Oct; 39(10): 1010428317734815. doi:10.1177/1010428317734815.; Ohkawa K., Tsukada Y., Abe T., Takada K., Hibi N. Overcoming effect of antibody against rat alpha-fetoprotein (AFP) on the growth of daunorubicin-resistant mutant rat ascites hepatoma cell line AH66. Int J Cancer. 1989; 44(3): 489–493. doi:10.1002/ijc.2910440319.; Астахов Д.В., Коваленко Н.А., Сологуб В.К., Большакова Т.Д., Северин С.Е., Шатверян Г.А., Гудовский Л.М. Определение антител к рецептору альфа-фетопротеина у онкологических больных. Вопросы биологической, медицинской и фармакологической химии. 1999; 2: 27–30.; Molina R., Auge J.M., Escudero J.M., Marrades R., Viñolas N., Carcereny E., Ramirez J., Filella X. Mucins CA 125, CA 19-9, CA 15.3, and TAG 72.3 as tumor markers in patinets with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol. 2008; 29(6): 371–80. doi:10.1159/000181180.; Molina R., Augé J.M., Bosch X., Escudero J.M., Viñolas N., Marrades R., Ramírez J., Carcereny E., Filella X. Usefulness of serum tumor markers, including progastrin-releasing peptide in patients with lung cancer. Correlation and histology. Tumour Biol. 2009; 30(3): 121–9. doi:10.1159/000224628.; European Group on Tumor markers. Consensus recommendations. Anticancer Res. 1999, 19: 2785–820.; Iwanicki-Caron I., Di Fiore F., Roque I., Astruc E., Stetiu M., Duclos A., Tougeron D., Saillard S., Thureau S., Benichou J., Paillot B., Basuyau J.P., Michel P. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol. 2008 Aug 1; 26(22): 3681–6. doi:10.1200/JCO.2007.15.0904.; Li C.S., Cheng B.C., Ge W., Gao J.F. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions. nt J Clin Pract. 2007 Mar; 61(3): 444–8. doi:10.1111/j.17421241.2006.01111.x.; Prados M.C., Alvarez-Sala R., Blasco R., Chivato T., García Satué J.L., García Río F.J., Gómez de Terrero F.J. Villamor The clinical value of neuron-specific enolase as a tumor marker in bronchoalveolar lavage. Cancer. 1994 Sep 1; 74(5): 1552–5. doi:10.1002/1097-0142(19940901)74:53.0.co;2-f.; Karnak D., Beder S., Kayacan O., Ibis E., Oflaz G. Neuron-specific enolase and lung cancer. Am J Clin Oncol. 2005 Dec; 28(6): 586–90.; Saba M.A., Valeh T., Ehteram H., Haddad Kashani H., Ghazi Zahedi M. Diagnostic Value of Neuron-Specific Enolase (NSE) and Cancer Antigen 15-3 (CA 15-3) in the Diagnosis of Pleural Effusions. Asian Pac J Cancer Prev. 2017 Jan 1; 18(1): 257–261. doi:10.22034/APJCP.2017.18.1.257.; Jørgensen L.G., Osterlind K., Genollá J., Gomm S.A., Hernández J.R., Johnson P.W., Løber J., Splinter T.A., Szturmowicz M. Serum neuron-specific enolase (S-NSE) and the prognosis in small cell lung cancer (SCLC): a combined multivariable analysis on data from nine centers. Br. J. Cancer 1996; 74; 463–467. doi:10.1038/bjc.1996.383.; Carney D.N., Teeling M. Neuron-specific enolase: how useful as a cancer marker? Eur J Cancer Clin Oncol. 1988 May; 24(5): 825–8.; https://www.siboncoj.ru/jour/article/view/1184

  3. 3
    Academic Journal

    المصدر: International Journal of Environmental and Ecological Engineering, 8.0(6), (2014-06-26) ; 14FR06, International Conference on Environmental, Biological, Ecological Sciences and Engineering, Paris, France, Jun 26-27, 2014

  4. 4
    Academic Journal
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15